Reishi Mushroom (Ganoderma lucidum) Extract Ameliorate Hyperglycemia and Liver/Kidney Functions in Streptozotocin-induced Type 2 Diabetic Rats

Abstract

iabetes is a metabolic condition characterized by hyperglycemia and insufficient insulin production or activity. Since ancient times, the reishi mushroom (Ganoderma lucidum) has been utilized as a traditional herbal treatment. Aim of the study: investigate the effectiveness of Ganoderma lucidum extract (GLE) to ameliorate hyperglycemia and liver/kidney functions in streptozotocin-induced type 2 diabetic rats. Six groups of adult male Sprague– Dawley rats were formed at random. Group 1: Normal rats with a normal diet. Group 2: Diabetic rats by injection Streptozotocin (STZ) and fed without intervention as a model control group, Groups 3-6: GLE, diabetic rats with intervention groups receiving GLE at doses of 200, 400, 600, and 800 mg/kg BW via oral gavage for 28 days. After GLE intervention, blood samples were tested for changes in hyperglycemia, glycosylated hemoglobin, insulin, liver, and kidney functioning. Results: Within the first two weeks of GLE intervention, blood glucose levels were reduced, and insulin levels in diabetic rats in the GLE group were considerably higher at four weeks than in the positive control group. Furthermore, it was discovered that GLE intervention significantly improved the liver and kidney functioning of diabetic rats. Conclusion: This research suggests that GLE consumption may help reduce blood glucose levels by boosting insulin production. Meanwhile, GLE therapy was linked to a reduction in diabetes problems in type 2 diabetic rats by improving their liver and renal functioning.